Price movement over the last 24 hours
AbbVie Inc vs First Trust Cloud Computing ETF — how do they compare? AbbVie Inc trades at $253.68 (market cap $449.91B), while First Trust Cloud Computing ETF trades at $137.95. The key difference: AbbVie Inc pays a 2.72% dividend while First Trust Cloud Computing ETF pays none, and AbbVie Inc is trading nearer its 52-week high, First Trust Cloud Computing ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | SKYY | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | — |
52-Week High | $261.07 | $155.17 |
52-Week Low | $184.85 | $104.16 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
SKYY, the First Trust Cloud Computing ETF, trades at $139.01, up 3.08% today, with a bullish technical signal from moving averages but mixed oscillators. The ETF provides diversified exposure to the cloud computing sector, which is benefiting from enterprise digital transformation and AI adoption. Recent news highlights strong inflows into technology ETFs and the launch of AI tools to aid investment decisions.
The outlook for SKYY is positive, driven by sustained demand for cloud services and AI integration, though risks include sector volatility and competitive pressures. Investors should monitor earnings growth of underlying holdings and broader tech sector trends for continued upside potential.
Trailing returns across standard periods
Latest headlines on both assets
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is designed to track the performance of companies involved in the cloud computing industry.
Read more on SKYY →